ERBB2 and neoplasm: Maron et al. found that in patients with HER2-amplified tumours via ctDNA and/or tissue-based NGS had improved OS when treated with HER-directed therapy, demonstrating the clinical utility of ctDNA as a prognostic biomarker [36].